Atara Biotherapeutics (ATRA) Revenue (2021 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Revenue came in at $516000.0 in Q1 2026, down 99.47% YoY from $98.1 million in Q1 2025, and down 67.65% on a QoQ basis from $1.6 million in Q4 2025.
Atara Biotherapeutics (ATRA) Revenue (2021 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 6 years of Revenue data on file, last reported at $516000.0 in Q1 2026.
- Quarterly Revenue fell 99.47% year-over-year to $516000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.1 million (down 88.41% YoY) and the FY2025 annual result came in at $120.8 million, down 6.33% from the prior year.
- Revenue slipped to $516000.0 in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $98.1 million in Q1 2025 to a low of -$3.0 million in Q4 2023.
- A 5-year average of $19.3 million and a median of $4.0 million in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2023 — Revenue tumbled 269.77% — and 2024, when it surged 17363.41%.
- Tracing ATRA's Revenue over 5 years: stood at $1.8 million in 2022, then plunged by 269.77% to -$3.0 million in 2023, then surged by 1188.14% to $32.8 million in 2024, then tumbled by 95.13% to $1.6 million in 2025, then sank by 67.65% to $516000.0 in 2026.
- The last three Revenue figures came in at $516000.0 (Q1 2026), $1.6 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 145.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.71 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.29 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 425.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 674.14 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 1.06 Bn |
| 10 | Atara Biotherapeutics | 140.71 Mn | 124.16 Mn | 439,000.00 | 630,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 630,000.00 |
| Mar 31, 2026 | 516,000.00 |
| Dec 31, 2025 | 1.60 Mn |
| Sep 30, 2025 | 3.45 Mn |
| Jun 30, 2025 | 17.58 Mn |
| Mar 31, 2025 | 98.15 Mn |
| Dec 31, 2024 | 32.75 Mn |
| Sep 30, 2024 | 40.19 Mn |
| Jun 30, 2024 | 28.64 Mn |
| Mar 31, 2024 | 27.36 Mn |
| Dec 31, 2023 | -3.01 Mn |
| Sep 30, 2023 | 2.02 Mn |
| Jun 30, 2023 | 164,000.00 |
| Mar 31, 2023 | 884,000.00 |
| Dec 31, 2022 | 1.77 Mn |
| Sep 30, 2022 | 4.46 Mn |
| Jun 30, 2022 | 51.58 Mn |
| Dec 31, 2021 | 7.55 Mn |
| Sep 30, 2021 | 5.37 Mn |
| Jun 30, 2021 | 3.87 Mn |